Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole in adolescents with symptomatic non-erosive gastroesophageal reflux disease
2012-001680-72Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexlansoprazole in gastroesophageal reflux disease (GERD) and Non-erosive Gastroesophageal Reflux Disease (NERD), sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events. Started Jul 2012; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on 2012-001680-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001680-72.